StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.66+0.06 (+3.75%)

Close on Nov 17, 2026Market cap $4.22MP/E –Yield –

Alaunos Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Alaunos Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -133666.7%. For fiscal 2025 it was -83520.0%, against -46790.0% the year before. The highest annual figure on record is -341.7% in fiscal 2017.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-83520.0%−36730.0
FY2024Dec 31, 2024-46790.0%+46790.0
FY2023Dec 31, 2023-93580.0%−92288.8
FY2022Dec 31, 2022-1291.2%+18495.4
FY2021Dec 31, 2021-19786.7%+16594.8
FY2018Dec 31, 2018-36381.5%−36039.9
FY2017Dec 31, 2017-341.7%+2067.6
FY2016Dec 31, 2016-2409.2%+9607.3
FY2012Dec 31, 2012-12016.5%−2454.6
FY2011Dec 31, 2011-9561.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-29766.7%+138433.3
Q1 FY2025Mar 31, 2025-53650.0%−2315450.0
Q4 FY2024Dec 31, 2024-18550.0%+200775.0
Q2 FY2024Jun 30, 2024-28225.0%+55038.6
Q1 FY2024Mar 31, 2024-168200.0%−167895.9
Q4 FY2023Dec 31, 20232261800.0%+2276279.5
Q2 FY2023Jun 30, 2023-219325.0%−218180.9
Q4 FY2022Dec 31, 2022-83263.6%−82162.0
Q3 FY2022Sep 30, 2022-304.1%+806.0
Q1 FY2018Mar 31, 2018-14479.5%−13248.5
Q4 FY2017Dec 31, 2017-1144.1%–
Q3 FY2017Sep 30, 2017-1101.6%–
Q2 FY2017Jun 30, 2017-1110.0%–
Q1 FY2017Mar 31, 2017-1230.9%–

More Alaunos Therapeutics figures

See a number that looks wrong?